The directors of Lookers have bought up shares in the car dealership, a week after investor confidence was shaken by a profit warning.

The chief executive, chief operating officer and a non-executive director of the company all snapped up shares on Friday, after the group's share price plunged when it said profits in the first half would be lower than market expectations.

Non-executive director Tony Bramall made the biggest purchase through his company Guernsey Investments Limited, spending about £1.6 million on more than four million shares.

This puts his stake in the company at 17.38%.

READ MORE: Car dealer profit warning

Chief executive Andy Bruce invested just over £75,000 to pick up 192,000 shares, while chief operating officer Nigel McMinn bought 200,000 shares for about £77,500.

It signals the confidence of the company's leadership during a rocky period, with both the profit warning and an ongoing Financial Conduct Authority (FCA) investigation weighing on investor sentiment.

Retail tycoon Philip Day has moved closer to taking high street retailer Bonmarche private after his Spectre Holdings group said it would apply to de-list the fashion brand.

After the closure of Philip Day's offer for the company on Friday - which values the business at £5.7 million - he said he either owned or had the backing of shareholders for around 93% of the company's shares.

READ MORE: Steven Brown Art firm goes into liquidation with loss of 21 jobs

Mr Day, who also owns Edinburgh Woollen Mill, Peacocks and Jane Norman, has eased past the 75% threshold needed to take the company private.

This means that Bonmarche could be taken off the stock exchange as early as August 6.

Shares in Bonmarche were up 0.8% to 12.1p.

GlaxoSmithKline has hailed a major step forward for an ovarian cancer drug it acquired last year, announcing that it has been effective in stopping the spread of ovarian cancer.

The announcement is a significant boost for the drugs giant, which has come under pressure from investors who are concerned that it is failing to keep pace with some of its industry peers.

GSK said Zejula demonstrated its effectiveness in stopping the spread of the cancer when taken as the first treatment after a patient has undergone chemotherapy.

It gained Zejula in December as part of its controversial 5.1 billion US dollar (£4 billion) acquisition of oncology-focused company Tesaro.